Details for Patent: 7,713,938

Which drugs does patent 7,713,938 protect, and when does it expire?

Patent 7,713,938 protects SYNJARDY XR, TRIJARDY XR, GLYXAMBI, JARDIANCE, and SYNJARDY, and is included in five NDAs.

Protection for SYNJARDY XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-one patent family members in thirty-two countries.

Summary for Patent: 7,713,938

Title:	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Abstract:	The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
Inventor(s):	Frank Himmelsbach, Sandra Schmid, Martin Schuehle, Hans-Jürgen Martin, Matthias Eckhardt
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US11/406,971
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,713,938
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 7,713,938

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No	7,713,938*PED				Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-002	Dec 9, 2016		RX	Yes	No	7,713,938*PED				Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-003	Dec 9, 2016		RX	Yes	No	7,713,938*PED				Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-004	Dec 9, 2016		RX	Yes	Yes	7,713,938*PED				Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No	7,713,938*PED				Y

Foreign Priority and PCT Information for Patent: 7,713,938

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	05009669	May 3, 2005
	05018012	Aug 19, 2005

International Family Members for US Patent 7,713,938

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	053720
Argentina	087208
Austria	E452883
Australia	2006243859
Brazil	PI0610994